India rejects compulsory license application for Sprycel
This article was originally published in Scrip
Executive Summary
India has rejected BDR Pharmaceuticals' application for a compulsory license (CL) for Bristol-Myers Squibb's anticancer, Sprycel (dasatinib), after the Indian firm failed to make a prima facie case for such a request.